Program
stapokibart
Also written as “CM310”, “Stapokibart” and “Stapokibart injection”.
Its studies are mostly in Dermatitis, Atopic · Rhinitis, Allergic, Seasonal · Rhinitis, Allergic · Nasal Polyps · Asthma, led by 3 companies.
Drug pageStapokibart: every studyAll 36 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Keymed Biosciencesits history only | 246 open or running | phase 3since Feb 17, 2022 | Mar 12, 2021 | Feb 2027phase 3 · NCT07106372 |
| Chengdu Kangnuoxing Biopharma,Inc.its history only | 33 open or running | phase 3since Sep 30, 2025 | Sep 30, 2025 | Dec 2026phase 3 · NCT07678931 |
| CSPC Pharmaceutical Groupits history only | 22 open or running | phase 3since Feb 27, 2023 | Feb 27, 2023 | Apr 29, 2032phase 3 · NCT06547333 |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of every company. Pick one to see its own:
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
Not listed one by one: 15 earlier studies, Mar 12, 2021 to Oct 30, 2023.
- Jan 19, 2023Named stapokibartINNProposed as its International Nonproprietary Name in WHO's List 128 · before, CM310
- Nov 29, 2023Phase 2 study in Dermatitis, AtopicKeymed Biosciences · NCT06162507 · 24 enrolled · China
- Nov 29, 2023Phase 1 study in HealthyKeymed Biosciences · NCT06161090 · 33 enrolled · China
- Dec 4, 2023Phase 2 study in Rhinitis, Allergic, SeasonalKeymed Biosciences · NCT06171074 · 100 planned · China
- Dec 5, 2023Phase 1 study in HealthyKeymed Biosciences · NCT06171048 · 236 planned · China
- Feb 18, 2024Phase 3 study in Dermatitis, AtopicKeymed Biosciences · NCT06277765 · 180 enrolled · China
- May 16, 2024Phase 3 study in Prurigo NodularisKeymed Biosciences · NCT06424470 · 200 enrolled · China
- Jul 2, 2024Phase 3 study in Dermatitis, AtopicKeymed Biosciences · NCT06495229 · 180 enrolled · China
- Jul 24, 2024Phase 2 study in Rhinitis, AllergicKeymed Biosciences · NCT06525597 · 120 planned · China
- Aug 7, 2024Phase 3 study in Pulmonary Disease, Chronic ObstructiveCSPC Pharmaceutical Group · NCT06547333 · 884 planned
- Apr 30, 2025Phase 3 study in Dermatitis, AtopicKeymed Biosciences · NCT06956196 · 240 planned · China
- Aug 5, 2025Phase 3 study in Dermatitis, AtopicKeymed Biosciences · NCT07106372 · 240 planned · China
- Sep 30, 2025Chengdu Kangnuoxing Biopharma,Inc.’s first study: phase 3 study in Pemphigoid, BullousNew to Chengdu Kangnuoxing Biopharma,Inc.Chengdu Kangnuoxing Biopharma,Inc. · NCT07210554 · 200 planned · China
- May 21, 2026Phase 2 study in Rhinitis, Allergic, SeasonalChengdu Kangnuoxing Biopharma,Inc. · NCT07617324 · 15 planned · China
- Jun 25, 2026Phase 3 study in Rhinitis, Allergic, SeasonalChengdu Kangnuoxing Biopharma,Inc. · NCT07678931 · 136 planned · China
Ahead
- Dec 2026Primary completion: phase 3 study in Rhinitis, Allergic, SeasonalChengdu Kangnuoxing Biopharma,Inc. · NCT07678931
- Feb 2027Primary completion: phase 3 study in Dermatitis, AtopicKeymed Biosciences · NCT07106372
- Mar 27, 2028Primary completion: phase 3 study in Pemphigoid, BullousChengdu Kangnuoxing Biopharma,Inc. · NCT07210554
- Apr 29, 2032Primary completion: phase 3 study in Pulmonary Disease, Chronic ObstructiveCSPC Pharmaceutical Group · NCT06547333
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 29 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07678931Rhinitis, Allergic, Seasonal · China | 3 | Recruiting | Chengdu Kangnuoxing Biopharma,Inc. | Dec 2026 | 136 |
| NCT07617324Rhinitis, Allergic, Seasonal · China | 2 | Not yet recruiting | Chengdu Kangnuoxing Biopharma,Inc. | Oct 2026 | 15 |
| NCT07210554Pemphigoid, Bullous · China | 3 | Not yet recruiting | Chengdu Kangnuoxing Biopharma,Inc. | Mar 27, 2028 | 200 |
| NCT07106372Dermatitis, Atopic · China | 3 | Not yet recruiting | Keymed Biosciences | Feb 2027 | 240 |
| NCT06956196Dermatitis, Atopic · China | 3 | Not yet recruiting | Keymed Biosciences | May 2026 | 240 |
| NCT06547333Pulmonary Disease, Chronic Obstructive | 3 | Not yet recruiting | CSPC Pharmaceutical Group | Apr 29, 2032 | 884 |
| NCT06525597Rhinitis, Allergic · China | 2 | Recruiting | Keymed Biosciences | Oct 30, 2025 | 120 |
| NCT06495229Dermatitis, Atopic · China | 3 | Active, not recruiting | Keymed Biosciences | Aug 30, 2026 | 180 |
| NCT06424470Prurigo Nodularis · China | 3 | Completed | Keymed Biosciences | Feb 11, 2026 | 200 |
| NCT06277765Dermatitis, Atopic · China | 3 | Completed | Keymed Biosciences | Jan 23, 2025 | 180 |
| NCT06171048Healthy · China | 1 | Not yet recruiting | Keymed Biosciences | Apr 30, 2025 | 236 |
| NCT06171074Rhinitis, Allergic, Seasonal · China | 2 | Not yet recruiting | Keymed Biosciences | Mar 30, 2025 | 100 |
| NCT06162507Dermatitis, Atopic · China | 2 | Completed | Keymed Biosciences | Jul 4, 2024 | 24 |
| NCT06161090Healthy · China | 1 | Completed | Keymed Biosciences | Jan 13, 2020 | 33 |
| NCT06116565Dermatitis, Atopic · China | 2 | Completed | Keymed Biosciences | Nov 26, 2025 | 263 |
| NCT05908721Rhinitis, Allergic · China | 2 | Completed | Keymed Biosciences | Dec 10, 2023 | 100 |
| NCT05908032Rhinitis, Allergic · China | 3 | Completed | Keymed Biosciences | Dec 4, 2023 | 108 |
| NCT05761028Moderate to Severe Asthma · China | 3 | Recruiting | CSPC Pharmaceutical Group | May 2032 | 600 |
| NCT05715320Dermatitis, Atopic · China | 2 | Completed | Keymed Biosciences | Jul 18, 2024 | 160 |
| NCT05702450Healthy · China | 1 | Completed | Keymed Biosciences | Jul 26, 2023 | 240 |
| NCT05579925Dermatitis, Atopic · China | 2 | Completed | Keymed Biosciences | Jul 28, 2023 | 24 |
| NCT05452343Chronic Pruritus of Unknown Origin | 2 | UNKNOWN | Keymed Biosciences | Mar 1, 2024 | 50 |
| NCT05265923Dermatitis, Atopic · China | 3 | Completed | Keymed Biosciences | Oct 31, 2023 | 500 |
| NCT05186909Asthma · China | 2 | Completed | Keymed Biosciences | Sep 13, 2023 | 52 |
| NCT05131464Chronic Rhinosinusitis With Nasal Polyps · China | 2 | Completed | Keymed Biosciences | Jan 31, 2024 | 46 |
| NCT04893707Dermatitis, Atopic · China | 2 | Completed | Keymed Biosciences | Feb 3, 2023 | 127 |
| NCT04893941Moderate-to-severe Atopic Dermatitis · China | 2 | Completed | Keymed Biosciences | Jan 22, 2021 | 39 |
| NCT04805411Dermatitis, Atopic · China | 2 | Completed | Keymed Biosciences | Nov 8, 2021 | 120 |
| NCT04805398Disease · China | 2 | Completed | Keymed Biosciences | Mar 18, 2022 | 56 |
How it is read
Names in the registry
- “CM310”, 22 entries
- “Stapokibart”, 2 entries
- “Stapokibart injection”, 2 entries
- “Stapokibatrt”, 2 entries
- “Stapokibart Injection”, 1 entry
Conditions, from the studies’ own filings
- Dermatitis, Atopic, 12 studies
- Rhinitis, Allergic, Seasonal, 3 studies
- Rhinitis, Allergic, 3 studies
- Nasal Polyps, 2 studies
- Asthma, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.